Filing Details
FibroBiologics, Inc. (NASDAQ:FBLG) filed a Form 8-K with the Securities and Exchange Commission on July 09, 2026, disclosing a material event.
8k filedNASDAQ:FBLG
FibroBiologics, Inc. (FBLG) Reports Material Event to SEC
Filing Details FibroBiologics, Inc. (NASDAQ:FBLG) filed a Form 8-K with the Securities and Exchange Commission on July 09, 2026, disclosing a material event. Market Context…
Market Context
FibroBiologics, Inc.'s stock currently trades at $0.86 with a market capitalization of $14.4M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for FibroBiologics, Inc.'s stock.
All SEC filings for FibroBiologics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View FBLG Stock Page
Frequently Asked Questions
Where can I read FBLG's SEC filings?
Browse all filings on our FBLG SEC filings page.
What types of SEC filings does FibroBiologics, Inc. file?
Public companies like FibroBiologics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.